213 related articles for article (PubMed ID: 20101205)
21. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
22. Identification of ANKRD11 as a p53 coactivator.
Neilsen PM; Cheney KM; Li CW; Chen JD; Cawrse JE; Schulz RB; Powell JA; Kumar R; Callen DF
J Cell Sci; 2008 Nov; 121(Pt 21):3541-52. PubMed ID: 18840648
[TBL] [Abstract][Full Text] [Related]
23. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
24. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
Osada H; Tatematsu Y; Sugito N; Horio Y; Takahashi T
Mol Carcinog; 2005 Dec; 44(4):233-41. PubMed ID: 16163707
[TBL] [Abstract][Full Text] [Related]
25. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers.
Filippova GN; Lindblom A; Meincke LJ; Klenova EM; Neiman PE; Collins SJ; Doggett NA; Lobanenkov VV
Genes Chromosomes Cancer; 1998 May; 22(1):26-36. PubMed ID: 9591631
[TBL] [Abstract][Full Text] [Related]
26. PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway.
Yu DH; Fan W; Liu G; Nguy V; Chatterton JE; Long S; Ke N; Meyhack B; Bruengger A; Brachat A; Wong-Staal F; Li QX
Exp Cell Res; 2006 Apr; 312(6):865-76. PubMed ID: 16413018
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation of the human retinoblastoma tumor suppressor gene promoter by CTCF.
De La Rosa-Velázquez IA; Rincón-Arano H; Benítez-Bribiesca L; Recillas-Targa F
Cancer Res; 2007 Mar; 67(6):2577-85. PubMed ID: 17363576
[TBL] [Abstract][Full Text] [Related]
28. CTCF negatively regulates HOXA10 expression in breast cancer cells.
Mustafa M; Lee JY; Kim MH
Biochem Biophys Res Commun; 2015 Nov; 467(4):828-34. PubMed ID: 26478432
[TBL] [Abstract][Full Text] [Related]
29. CTCF mediates the TERT enhancer-promoter interactions in lung cancer cells: identification of a novel enhancer region involved in the regulation of TERT gene.
Eldholm V; Haugen A; Zienolddiny S
Int J Cancer; 2014 May; 134(10):2305-13. PubMed ID: 24174344
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic repression of RARRES1 is mediated by methylation of a proximal promoter and a loss of CTCF binding.
Peng Z; Shen R; Li YW; Teng KY; Shapiro CL; Lin HJ
PLoS One; 2012; 7(5):e36891. PubMed ID: 22615834
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional repression by the proximal exonic region at the human TERT gene.
Wong TC; Sokol ES; Schep AN; Punjiya M; Tran DA; Allan D; Drewell RA
Gene; 2011 Oct; 486(1-2):65-73. PubMed ID: 21787851
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding.
Victoria-Acosta G; Vazquez-Santillan K; Jimenez-Hernandez L; Muñoz-Galindo L; Maldonado V; Martinez-Ruiz GU; Melendez-Zajgla J
Sci Rep; 2015 Oct; 5():14838. PubMed ID: 26443201
[TBL] [Abstract][Full Text] [Related]
33. Gain of DNA methylation is enhanced in the absence of CTCF at the human retinoblastoma gene promoter.
Dávalos-Salas M; Furlan-Magaril M; González-Buendía E; Valdes-Quezada C; Ayala-Ortega E; Recillas-Targa F
BMC Cancer; 2011 Jun; 11():232. PubMed ID: 21663659
[TBL] [Abstract][Full Text] [Related]
34. The tumor suppressor role of CTCF.
Fiorentino FP; Giordano A
J Cell Physiol; 2012 Feb; 227(2):479-92. PubMed ID: 21465478
[TBL] [Abstract][Full Text] [Related]
35. [Preliminary study of p53 gene promoter binding site of activator protein-1 in A549 cell lines by chromatin immunoprecipitation].
Shen F; Li ZT; Wu YM; Wu WD
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Aug; 26(8):453-6. PubMed ID: 19358752
[TBL] [Abstract][Full Text] [Related]
36. CTCF depletion alters chromatin structure and transcription of myeloid-specific factors.
Ouboussad L; Kreuz S; Lefevre PF
J Mol Cell Biol; 2013 Oct; 5(5):308-22. PubMed ID: 23933634
[TBL] [Abstract][Full Text] [Related]
37. Disruption of CTCF at the miR-125b1 locus in gynecological cancers.
Soto-Reyes E; González-Barrios R; Cisneros-Soberanis F; Herrera-Goepfert R; Pérez V; Cantú D; Prada D; Castro C; Recillas-Targa F; Herrera LA
BMC Cancer; 2012 Jan; 12():40. PubMed ID: 22277129
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic complexity during the zebrafish mid-blastula transition.
Andersen IS; Ostrup O; Lindeman LC; Aanes H; Reiner AH; Mathavan S; Aleström P; Collas P
Biochem Biophys Res Commun; 2012 Jan; 417(4):1139-44. PubMed ID: 22209792
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of miR-181c by DNA methylation in glioblastoma cell lines.
Ayala-Ortega E; Arzate-Mejía R; Pérez-Molina R; González-Buendía E; Meier K; Guerrero G; Recillas-Targa F
BMC Cancer; 2016 Mar; 16():226. PubMed ID: 26983574
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic boundaries of tumour suppressor gene promoters: the CTCF connection and its role in carcinogenesis.
Recillas-Targa F; De La Rosa-Velázquez IA; Soto-Reyes E; Benítez-Bribiesca L
J Cell Mol Med; 2006; 10(3):554-68. PubMed ID: 16989720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
